https://www.selleckchem.com/pr....oducts/vafidemstat.h
Immune checkpoint inhibitors (ICI) has achieved remarkable clinical benefit in advanced lung adenocarcinoma (LUAD). However, effective clinical use of ICI agents is encumbered by the high rate of innate resistance. The aim of our research is to identify significant gene mutations which can predict clinical benefit of immune checkpoint inhibitors in LUAD. The "mafComapre" function of "MafTools" package was used to screen the differentially mutated genes between durable clinical benefit (DC group and no durable clinical benefit (NDB
Like
Comment
Share
